RxDoctor Payments Data

Kelly Allen

Psychiatric/Mental Health · Warren, PANPI 1033549605

Payments from drug & device makers

$5,412in general payments, 2019–2025

Across 299 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$860
  • Alkermes, Inc.$768
  • Corium, LLC$561
  • AbbVie$528
  • Axsome Therapeutics, Inc.$478
  • Supernus Pharmaceuticals, Inc.$431
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$5,30098%
  • Education$1112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,412 in reported general payments places this provider in the 90th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

See all psychiatric/mental health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$5,511
Medicare patients
33
Services billed
102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole13$40,020
RexultiBrexpiprazole11$14,918
TrintellixVortioxetine Hydrobromide22$11,771
Depakote ErDivalproex Sodium13$10,054
Lurasidone Hcl15$5,007
Vilazodone Hcl36$1,987
Desvenlafaxine Succinate ErDesvenlafaxine Succinate42$1,413
Venlafaxine Hcl ErVenlafaxine Hcl134$1,343
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine19$946
Duloxetine Hcl49$786
Trazodone Hcl87$743
Clonazepam55$713
Lorazepam112$713
Atomoxetine Hcl13$700
Methylphenidate ErMethylphenidate Hcl11$530

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$406$54,93824 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$58$11,77122 claims
Almatica Pharma LLCSertraline Hcl$21$22042 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.

Other psychiatric/mental health in Warren

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →